Walgreens Boots Alliance, Inc.(WBA) Stock Research - Grey Stern Research
Loading...

Walgreens Boots Alliance, Inc. (WBA) Stock Analysis

$18.18 (-0.87%)

WBA Financial Performance


Use the table below to view Walgreens Boots Alliance, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $18.34 -
52 Week Low $17.12 -
52 Week High $32.89 -
Market Cap $15.8 Billion 1/9
Gross Margin 17% 4/9
Profit Margin -16% 5/9
EBITDA margin 1% 2/9
Q2 - 2024 Revenue $37.1 Billion 1/9
Q2 - 2024 Earnings -$5.9 Billion 9/9
Q2 - 2024 Free Cash Flow -$989.0 Billion 8/9
Trailing 4 Quarters Revenue $173.5 Billion 1/9
Trailing 4 Quarters Earnings -$6.2 Billion 9/9
Quarterly Earnings Growth -1200% 8/9
Annual Earnings Growth 43% 2/9
Quarterly Revenue Growth 6% 3/9
Annual Revenue Growth 29% 1/9
Cash On Hand $668.0 Million 1/9
Short Term Debt $4.3 Billion 1/9
Long Term Debt $7.5 Billion 1/9

Walgreens Boots Alliance, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Walgreens Boots Alliance, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 1/9
PS 0.09 8/9
PB 1.03 5/9
PC 23.69 2/9
Liabilities to Equity 5.11 2/9
ROA -0.07 3/9
ROE -0.46 6/9
Current Ratio 1.22 4/9
Quick Ratio 0.01 6/9
Long Term Debt to Equity 0.56 2/9
Debt to Equity 2.57 2/9
Burn Rate 0.09 6/9
Cash to Cap 0.04 7/9
CCR 0.17 5/9
EV to EBITDA 103.07 1/9
EV to Revenue 0.29 4/9

Company Details

Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through two segments, the United States and International. The United States segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides central specialty pharmacy services and mail services. As of August 31, 2021, this segment operated 8,965 retail stores under the Walgreens and Duane Reade brands in the United States; and five specialty pharmacies. The International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty retail stores and optical practices, as well as through boots.com and an integrated mobile application. It also engages in pharmaceutical wholesaling and distribution business in Germany. As of August 31, 2021, this segment operated 4,031 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 548 optical practices, including 160 on a franchise basis. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.

CEO: Mr. Stefano Pessina

Website: https://www.walgreensbootsalliance.com

Address: 108 Wilmot Rd Deerfield, ILLINOIS

Exchange: NASDAQ Global Select

Industry: Pharmaceutical Retailers

Walgreens Boots Alliance, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Walgreens Boots Alliance, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Rite Aid Corporation RAD $36.8 Million
PetMed Express, Inc. PETS $96.9 Million
111, Inc. YI $113.7 Million
BIMI International Medical Inc. BIMI $14.6 Million
TRxADE HEALTH, Inc. MEDS $8.2 Million
MedAvail Holdings, Inc. MDVL $2.9 Million
High Tide Inc. HITI $166.4 Million
Leafly Holdings, Inc. LFLY $4.5 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
WBA Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 37.1 Billion -$5.9 Billion
Q1 2024 $ 36.7 Billion -$67.0 Million
Q4 2023 $ 64.4 Billion -$180.0 Million
Q3 2023 $ 35.4 Billion -$52.0 Million
Q2 2023 $ 34.9 Billion $537.0 Million
Q1 2023 $ 33.4 Billion -$3.8 Billion
Q4 2022 $ 32.4 Billion -$887.0 Million
Q3 2022 $ 32.6 Billion $289.0 Million

View All

WBA Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $668.0 Million $84.2 Billion $34.6 Billion $15.4 Billion
Q1 2024 $784.0 Million $97.8 Billion $33.7 Billion $27.8 Billion
Q4 2023 $728.0 Million $96.6 Billion $33.5 Billion $28.3 Billion
Q3 2023 $871.0 Million $98.6 Billion $36.4 Billion $29.4 Billion
Q2 2023 $1.1 Billion $100.5 Billion $37.6 Billion $29.4 Billion
Q1 2023 $2.3 Billion $92.9 Billion $35.5 Billion $24.6 Billion
Q4 2022 $1.4 Billion $90.1 Billion $35.5 Billion $29.4 Billion
Q3 2022 $2.3 Billion $92.8 Billion $37.3 Billion $30.4 Billion

View All

WBA Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 -$989.0 Million -$352.0 Million -$116.0 Million
Q1 2024 -$787.0 Million -$506.0 Million -$10.0 Million
Q4 2023 $36.0 Million $0 $36.0 Million
Q3 2023 -$545.0 Million -$525.0 Million -$876.0 Million
Q2 2023 $248.0 Million -$498.0 Million -$2.3 Billion
Q1 2023 -$117.0 Million -$610.0 Million $1.8 Billion
Q3 2022 $1.3 Billion -$371.0 Million $2.5 Billion
Q2 2022 $669.0 Million -$416.0 Million -$2.2 Billion

View All